You are here

Article info

Article menu

Download PDFPDF

Brief communication
Efficacy and safety of rituximab biosimilar in refractory lupus

Authors

  • Nantakarn Pongtarakulpanit Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand PubMed articlesGoogle scholar articles
  • Prapaporn Pisitkun Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand PubMed articlesGoogle scholar articles
  • Pintip Ngamjanyaporn Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Pintip Ngamjanyaporn; pintip.nga{at}mahidol.ac.th
View Full Text

Citation

Pongtarakulpanit N, Pisitkun P, Ngamjanyaporn P
Efficacy and safety of rituximab biosimilar in refractory lupus
Lupus Science & Medicine 2020;7:e000442. doi: 10.1136/lupus-2020-000442

Publication history

  • Received August 28, 2020
  • Revision received October 14, 2020
  • Accepted October 21, 2020
  • First published November 2, 2020.
Online issue publication 
January 04, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.